Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cryo-Cell International, Inc. (CCEL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.75+0.50 (+9.52%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.25
Open5.42
Bid5.24 x 1000
Ask7.08 x 1200
Day's Range5.25 - 5.79
52 Week Range5.00 - 14.16
Volume4,401
Avg. Volume3,645
Market Cap49.045M
Beta (5Y Monthly)0.58
PE Ratio (TTM)11.98
EPS (TTM)0.48
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Cord Blood Banking Leader Cryo-Cell Announces Transfer to the NYSE American Stock Exchange

    OLDSMAR, Fla., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”, the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange on August 30, 2022. David Portnoy, Chairman and Co-CEO of Cryo-Cell, said, “The New York Stock Exchange has been trading stocks for over 225 years and is

  • GlobeNewswire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2022 Financial Results

    OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2022. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2022 were $7.63 million compared to $7.21 million for the second quarter of fiscal 2021, a 6% increase. The revenues for the second

  • GlobeNewswire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2022 Financial Results

    OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022. Financial Results Revenue The revenues for the first quarter of fiscal 2022 were $7.26 million compared to $6.86 million for the first quarter of fiscal 2021. The revenues for the first quarter of fiscal 2022 co

Advertisement
Advertisement